Skip to Main Content
Sign in to myUHN Patient Portal

Clinical Trials Search Results

 

 

3888285075411/22/2017 2:42:57 PMThe breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:42:57 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3888304025311/22/2017 2:42:17 PMincluding a synchronous contralateral breast cancer (Note Patients found to have a contralateral breast cancer on study imaging following STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:42:17 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3887752179311/22/2017 2:34:44 PMwidespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:34:44 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3888945885211/22/2017 2:42:17 PMwho are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:42:17 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3887715743511/22/2017 2:36:00 PMALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging but is not specific enough to detect a difference across all breast tumor types STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:36:00 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3887185744411/22/2017 2:36:18 PM2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of Benign breast disease, LCIS or DCIS of contralateral breast is allowed STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:36:18 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3887595751011/22/2017 2:38:05 PMHER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Women (≥18 years of age) with metastatic breast cancer not amenable to curative STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:38:05 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3886432256211/22/2017 2:44:04 PMWith Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:44:04 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3886564223411/22/2017 2:43:55 PMActivity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer in women with advanced or metastatic ER+ breast cancer, who have disease that has STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:43:55 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
3888165752611/22/2017 2:38:28 PM15-20% of early breast cancers have high levels of a protein called HER2 which is that, in women receiving treatment for breast cancer, heart edema detected by MRI at STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca11/22/2017 2:38:28 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/16/2017 6:07 AM